Identification of human tumor antigens recognized by T-cells and their use for immunotherapy

Yutaka Kawakami

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Identification of human tumor antigens led to development of new immunotherapies for patients with cancer. Identification of T-cell epitopes allowed us to monitor antitumor T-cell responses quantitatively and qualitatively during immunotherapy as well as to develop more efficient immunotherapies with sufficient amounts of antigens in more immunogenic forms. Various immunotherapies, passive immunotherapies, including adoptive transfer of tumor reactive T-cells or allogeneic antigen-specific donor T-cells, and active immunization with identified tumor antigens or dendritic cells pulsed with tumor antigens are being evaluated in clinical trials. Although tumor regression has been observed in some patients, further improvement is required.

Original languageEnglish
Pages (from-to)427-434
Number of pages8
JournalInternational Journal of Hematology
Volume77
Issue number5
Publication statusPublished - 2003 Jun

Fingerprint

Forensic Anthropology
Neoplasm Antigens
Immunotherapy
T-Lymphocytes
Antigens
Neoplasms
T-Lymphocyte Epitopes
Passive Immunization
Adoptive Transfer
Dendritic Cells
Vaccination
Tissue Donors
Clinical Trials

Keywords

  • Dendritic cells
  • Graft versus leukemia
  • Immunotherapy
  • T-cells
  • Tumor antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Identification of human tumor antigens recognized by T-cells and their use for immunotherapy. / Kawakami, Yutaka.

In: International Journal of Hematology, Vol. 77, No. 5, 06.2003, p. 427-434.

Research output: Contribution to journalArticle

@article{b21c3cff184743bfa1cef2f8c5a5b7a9,
title = "Identification of human tumor antigens recognized by T-cells and their use for immunotherapy",
abstract = "Identification of human tumor antigens led to development of new immunotherapies for patients with cancer. Identification of T-cell epitopes allowed us to monitor antitumor T-cell responses quantitatively and qualitatively during immunotherapy as well as to develop more efficient immunotherapies with sufficient amounts of antigens in more immunogenic forms. Various immunotherapies, passive immunotherapies, including adoptive transfer of tumor reactive T-cells or allogeneic antigen-specific donor T-cells, and active immunization with identified tumor antigens or dendritic cells pulsed with tumor antigens are being evaluated in clinical trials. Although tumor regression has been observed in some patients, further improvement is required.",
keywords = "Dendritic cells, Graft versus leukemia, Immunotherapy, T-cells, Tumor antigens",
author = "Yutaka Kawakami",
year = "2003",
month = "6",
language = "English",
volume = "77",
pages = "427--434",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Identification of human tumor antigens recognized by T-cells and their use for immunotherapy

AU - Kawakami, Yutaka

PY - 2003/6

Y1 - 2003/6

N2 - Identification of human tumor antigens led to development of new immunotherapies for patients with cancer. Identification of T-cell epitopes allowed us to monitor antitumor T-cell responses quantitatively and qualitatively during immunotherapy as well as to develop more efficient immunotherapies with sufficient amounts of antigens in more immunogenic forms. Various immunotherapies, passive immunotherapies, including adoptive transfer of tumor reactive T-cells or allogeneic antigen-specific donor T-cells, and active immunization with identified tumor antigens or dendritic cells pulsed with tumor antigens are being evaluated in clinical trials. Although tumor regression has been observed in some patients, further improvement is required.

AB - Identification of human tumor antigens led to development of new immunotherapies for patients with cancer. Identification of T-cell epitopes allowed us to monitor antitumor T-cell responses quantitatively and qualitatively during immunotherapy as well as to develop more efficient immunotherapies with sufficient amounts of antigens in more immunogenic forms. Various immunotherapies, passive immunotherapies, including adoptive transfer of tumor reactive T-cells or allogeneic antigen-specific donor T-cells, and active immunization with identified tumor antigens or dendritic cells pulsed with tumor antigens are being evaluated in clinical trials. Although tumor regression has been observed in some patients, further improvement is required.

KW - Dendritic cells

KW - Graft versus leukemia

KW - Immunotherapy

KW - T-cells

KW - Tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=0038346696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038346696&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 427

EP - 434

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -